Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityNo recent work listed

Xiaojun Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8646-7060; OpenAlex author ID A5101957309. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2019: 4 papers · 2020: 8 papers · 2021: 2 papers · 2022: none · 2023: 2 papers

Papers 16

  1. IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer. Last author DOI 10.1186/s12967-023-04800-5↗
  2. Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score matching analysis. Last author DOI 10.1186/s40001-023-01572-y↗
  3. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.014↗
  4. Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection. Last author DOI 10.1155/2021/3809095↗
  5. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs… Co-author DOI 10.1002/cam4.3119↗
  6. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Co-author DOI 10.1002/ctm2.39↗
  7. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score ma… Co-author DOI 10.1016/j.pan.2020.02.009↗
  8. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00006↗
  9. Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessmen… Co-author DOI 10.3389/fonc.2020.00590↗
  10. A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After … Co-author DOI 10.3389/fonc.2020.00952↗
  11. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. Co-author DOI 10.3389/fonc.2020.01564↗
  12. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.622318↗
  13. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity sco… Co-author DOI 10.1186/s12885-019-5607-3↗
  14. Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis. Last author DOI 10.1186/s12885-019-5744-8↗
  15. Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study. Last author DOI 10.2139/ssrn.3266972↗
  16. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Co-author DOI 10.3389/fonc.2019.01197↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chaobin He · 14 shared papers, 2019–2021 · strength 1.97
  2. Shengping Li · 11 shared papers, 2019–2021 · strength 1.52
  3. Xin Huang · 6 shared papers, 2019–2021 · strength 0.85
  4. Shuxin Sun · 4 shared papers, 2019–2020 · strength 0.53
  5. Bokang Cui · 3 shared papers, 2019–2023 · strength 0.51
  6. Xiaohui Li · 1 shared paper, 2023 · strength 0.20
  7. Xiaohui Li · 1 shared paper, 2023 · strength 0.20
  8. Enliang Zhou · 1 shared paper, 2023 · strength 0.20
  9. Yu Zhang · 1 shared paper, 2019 · strength 0.14
  10. Yu Zhang · 1 shared paper, 2020 · strength 0.13
  11. Xiang‐Ming Lao · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.